This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
5 Consumer Staples Stocks to Buy as Fed Keeps Interest Rates Unchanged
by Ritujay Ghosh
As Fed holds rates steady amid global tensions, PM, KO, and other low-beta consumer staples shine as safer bets.
Can Philip Morris Rely on Pricing to Drive 2025 EPS Growth?
by Zacks Equity Research
PM lifts its 2025 EPS forecast after a strong first quarter, but can pricing alone keep driving growth through year-end?
Buy 5 High-Yielding Giant Consumer Staples Stocks for a Stable Portfolio
by Nalak Das
Add stability to your portfolio with KO, PM, MDLZ, MO, and CTVA as high-yield consumer staples poised for steady 2025 growth.
Altria Trades at a Bargain: Is it a Good Time to Buy the Stock?
by Ansuiya Mohta
MO trades at a steep discount to peers and shows bullish momentum, making it a potential value play in tobacco's shift to smoke-free.
Illicit E-Vapors Cloud Altira's Smoke-Free Ambitions: What's Next?
by Zacks Equity Research
MO's smoke-free push is under threat as illicit flavored e-vapor products dominate a growing U.S. nicotine market.
Top Research Reports for Alphabet, IBM & RTX
by Mark Vickery
GOOGL, IBM and RTX lead today's Zacks research, with AI, cloud, and defense backlogs fueling strong long-term prospects.
ZYN and IQOS Scale Up: Is Philip Morris Leading the Industry Reset?
by Ansuiya Mohta
PM sees smoke-free products drive 44% of Q1 profit as ZYN and IQOS momentum redefines its future beyond tobacco.
Altria's Smokeable Segment Shrinks: Is it Time to Pivot Faster?
by Ansuiya Mohta
MO's cigarette sales tumble amid inflation and rising e-vapor use, raising urgency for a faster smoke-free pivot.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for LVHD
Here's Why Altria (MO) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $59.36, moving +0.08% from the previous trading session.
Here's Why Altria (MO) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Philip Morris Stock Records 50% YTD Surge: Is it Too Late to Buy?
by Ansuiya Mohta
PM stock soars 50.1% year to date, fueled by smoke-free growth, premium pricing and bullish earnings momentum.
Is Altria's on! Pouch Gaining Enough Steam in Oral Tobacco?
by Ansuiya Mohta
With on! pouch shipments up and market share climbing, MO strengthens its position in smoke-free nicotine.
Can Smoke-Free Products Power Philip Morris' Next Decade of Growth?
by Zacks Equity Research
PM's smoke-free segment drives 33.1% gross profit growth in Q1, signaling a bold pivot beyond cigarettes.
Altria Group, Inc. (MO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Altria (MO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Altria (MO) Up 0.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for LVHD
Is Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPHD
Should Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPHD
Why Altria (MO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors Heavily Search Altria Group, Inc. (MO): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Altria (MO). This makes it worthwhile to examine what the stock has in store.
Altria vs. Philip Morris: Which Tobacco Stock Is a Better Buy Now?
by Ansuiya Mohta
Philip Morris leads in terms of its global growth and its smoke-free future strategy, making it a strong long-term buy.